Borealis Biosciences Appoints Christian Hordo as CEO and Secures $30M in Series A Extension

Vancouver, British Columbia & Seattle, December 30, 2024 (Business Wire) -- Borealis Biosciences has appointed Christian Hordo as CEO to lead the company’s mission in advancing RNA therapies for kidney diseases. Hordo, a seasoned leader in the biopharma industry, takes the helm following a $30 million infusion through an extension of its Series A financing, bringing the total capital raised to $180 million. The Series A round was led by Westlake BioPartners and follows a successful emergence from stealth earlier this year, which also saw $150 million in initial Series A funding from Versant Ventures and Novartis AG. Alongside the leadership appointment and funding, Borealis has also expanded its board with the addition of three new directors: David Allison, Ph.D., Tom Frohlich, and Catherine Thut, Ph.D.

Read full article here.